Peter R. Kowey, MD

Photo of Peter Kowey

Email:  KoweyP@mlhs.org

Phone: 484.476.2684

Department: Faculty

Association: Resident Faculty

View clinical profile on mainlinehealth.org

Education:

  • B.S., Biology, St. Joseph's College, Philadelphia, PA, 1971
  • M.D., University of Pennsylvania, Philadelphia, PA, 1975

Current Appointments:

  • 2009 to Present: Professor, Lankenau Institute for Medical Research
  • 2008 to Present: William Wikoff Smith Chair in Cardiovascular Research
  • 2000 to Present: President, The Heart Center of Lankenau, Bryn Mawr, and Paoli Hospitals
  • 1999 to Present: Chief, Division of Cardiovascular Diseases, Main Line Health
  • 1990 to Present: Professor of Medicine and Clinical Pharmacology, Jefferson Medical College, Thomas Jefferson University

Selected Publications

  1. Mohammed KS, Kowey PR, Musco S. Adjuvant therapy for atrial fibrillation. Future Cardiol. 2010 Jan;6(1):67-81. 
  2. Patel C, Yan GX, Kocovic D, Kowey PR. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):705-11; discussion 712. 
  3. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9.
  4. Patel C, Burke JF, Patel H, Gupta P, Kowey PR, Antzelevitch C, Yan GX. Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol. 2009 Feb;2(1):80-8.
  5. Cushing DJ, Adams MP, Cooper WD, Zhang B, Lipicky RJ, Kowey PR. Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol. 2009 Oct 15;104(8):1152-7. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009 Aug 18;120(7):636-44. Review.
  6. Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J. 2009 Aug;158(2):163-169.e1-3.
  7. Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ, Kudenchuk PJ, Kowey PR. Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs. Cardiovasc Toxicol. 2009 Sep;9(3):126-33. Epub 2009 Jun 25.
  8. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron EB, Lee KL, Goldman L; MOST investigators. Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: data from the Mode Selection Trial (MOST). Am Heart J. 2009 Jul;158(1):78-83.e2. 
  9. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009 May;157(5):827-36, 836.e1. Review.
  10. Sarapa N, Gussak I, Vajdic B, George S, Hadzievski L, Francom SF, Kowey P. Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. J Electrocardiol. 2009 Jul-Aug;42(4):358-66. Epub 2009 Apr 10. 
  11. Link M, Kowey P. One small step. Pacing Clin Electrophysiol. 2009 Mar;32(3):291-3. 
  12. Cushing DJ, Adams MP, Cooper WD, Kowey PR, Lipicky RJ. Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol. 2009 Apr;49(4):407-15. Epub 2009 Feb 26. 
  13. Cushing DJ, Kowey PR, Cooper WD, Massey BW, Gralinski MR, Lipicky RJ. PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol. 2009 Apr 1;607(1-3):167-72. Epub 2009 Feb 14.
  14. Zhu TG, Patel C, Martin S, Quan X, Wu Y, Burke JF, Chernick M, Kowey PR, Yan GX. Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. Eur Heart J. 2009 Feb;30(3):372-80. Epub 2009 Jan 15.
  15. Conway EL, Musco S, Kowey PR. Drug therapy for atrial fibrillation. Cardiol Clin. 2009 Feb;27(1):109-23, ix.
  16. Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol. 2008 Sep 22;102(6A):12H-19H. Review.
  17. Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM, Holroyde MJ, Kowey P; Shock Inhibition Evaluation with Azimilide Investigators. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol. 2008 Sep 23;52(13):1076-83.
  18. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008 Nov;19(11):1220-6. Review. 
  19. Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008 Aug;156(2):241-7. 

 

 
Main Line Health